When tests don’t fit the rules: regulatory challenges for agnostic metagenomic next-generation sequencing in infectious diseases diagnostics
Journal of Clinical Microbiology · 11.11.2026 · 64 (11)
DOI: 10.1128/jcm.00987-26 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Microbiology, erschienen am 11.11.2026. Verfasst von Nick P G Gauthier und 6 weiteren Autor:innen. Beteiligte Einrichtung: BugSeq Bioinformatics Inc., Vancouver, Canada. Hauptthemen laut MEDLINE: Metagenomics, High-Throughput Nucleotide Sequencing, Communicable Diseases, Molecular Diagnostic Techniques. Die Arbeit nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Metagenomic next-generation sequencing (mNGS) enables agnostic detection of bacteria, viruses, fungi, and parasites from clinical specimens. Patient access is restricted due to their current regulatory classification as Laboratory Developed Tests, which are offered by a limited number of laboratories. While patient access may be expanded through Food and Drug Administration authorization of mNGS-based in vitro diagnostics, some regulatory requirements for achieving this classification can be challenging to apply due to the agnostic nature of mNGS. For example, existing guidelines recommend organism-by-organism performance characterization similar to targeted molecular tests involving fixed analytes with stable detection thresholds. This minireview synthesizes validation and regulatory challenges unique to mNGS-based diagnostics and describes how laboratories and developers currently navigate available pathways. We focus on core analytical and clinical validation challenges, including discussion on the central role of bioinformatics pipelines and reference databases. We then summarize practical considerations for regulatory engagement, labeling, clinical-facing reporting, and alignment of mNGS assays to existing quality system frameworks. Finally, we outline future oversight considerations, including the need to distinguish mNGS from multiplexed PCR paradigms and the potential value of modular, component-based regulatory approaches that separately evaluate reagents, instruments, software, and databases, enabling system-level oversight rather than organism-by-organism validation. Together, these considerations aim to support risk-appropriate, scalable oversight, and accelerate adoption of mNGS in clinical microbiology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- BugSeq Bioinformatics Inc., Vancouver, Canada.
- Columbia University, New York, New York, USA.
- Vanderbilt Health, Nashville, Tennessee, USA.
- ASM, Washington, DC, USA.
- Emory University, Atlanta, Georgia, USA.
ORCID-Profile: David C Gaston, Colleen S Kraft, Dev Mittar
Zitieren
APA
Gauthier, N. P. G., Kapoor, V., Gaston, D. C., Prasad, N., Nwaobia, P., Kraft, C. S., & Mittar, D. (2026). When tests don’t fit the rules: regulatory challenges for agnostic metagenomic next-generation sequencing in infectious diseases diagnostics. Journal of Clinical Microbiology, 64(11). https://doi.org/10.1128/jcm.00987-26
Vancouver
Gauthier NPG, Kapoor V, Gaston DC, Prasad N, Nwaobia P, Kraft CS, et al. When tests don’t fit the rules: regulatory challenges for agnostic metagenomic next-generation sequencing in infectious diseases diagnostics. Journal of Clinical Microbiology. 2026;64(11). doi:10.1128/jcm.00987-26
BibTeX
@article{Gauthier2026,
author = {Gauthier, Nick P G and Kapoor, Vishal and Gaston, David C and Prasad, Neha and Nwaobia, Precious and Kraft, Colleen S and Mittar, Dev},
title = {When tests don’t fit the rules: regulatory challenges for agnostic metagenomic next-generation sequencing in infectious diseases diagnostics},
journal = {Journal of Clinical Microbiology},
year = {2026},
volume = {64},
number = {11},
doi = {10.1128/jcm.00987-26}
}
EUVIMED